[go: up one dir, main page]

WO2002012475A3 - Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees - Google Patents

Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees Download PDF

Info

Publication number
WO2002012475A3
WO2002012475A3 PCT/US2001/021109 US0121109W WO0212475A3 WO 2002012475 A3 WO2002012475 A3 WO 2002012475A3 US 0121109 W US0121109 W US 0121109W WO 0212475 A3 WO0212475 A3 WO 0212475A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic uses
homologous polypeptides
related factor
cerebellin
similarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021109
Other languages
English (en)
Other versions
WO2002012475A2 (fr
Inventor
Eric Wen Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU2001280464A priority Critical patent/AU2001280464A1/en
Priority to EP01958853A priority patent/EP1328632A2/fr
Publication of WO2002012475A2 publication Critical patent/WO2002012475A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002012475A3 publication Critical patent/WO2002012475A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des séquences d'acides nucléiques codant la nouvelle protéine humaine du type CRF présentant quelques similitudes avec la cérébelline. Ces nouveaux acides nucléiques sont utilisés dans la construction des vecteurs ADN et des cellules hôtes revendiqués selon l'invention et dans la préparation des protéines et des anticorps recombinants revendiqués.
PCT/US2001/021109 2000-08-04 2001-07-23 Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees Ceased WO2002012475A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001280464A AU2001280464A1 (en) 2000-08-04 2001-07-23 C1q-related factor, homologous polypeptides and therapeutic uses thereof
EP01958853A EP1328632A2 (fr) 2000-08-04 2001-07-23 Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22323600P 2000-08-04 2000-08-04
US60/223,236 2000-08-04

Publications (2)

Publication Number Publication Date
WO2002012475A2 WO2002012475A2 (fr) 2002-02-14
WO2002012475A3 true WO2002012475A3 (fr) 2003-05-15

Family

ID=22835644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021109 Ceased WO2002012475A2 (fr) 2000-08-04 2001-07-23 Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees

Country Status (3)

Country Link
EP (1) EP1328632A2 (fr)
AU (1) AU2001280464A1 (fr)
WO (1) WO2002012475A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044373A2 (fr) * 2000-11-29 2002-06-06 Zymogenetics, Inc. Proteine zacrp12 associee a un complement d'adipocyte
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
ES2932777T3 (es) * 2014-01-31 2023-01-25 Cytomx Therapeutics Inc Sustratos de matriptasa y activador del plasminógeno-u y otros motivos escindibles y métodos de uso de los mismos
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
KR20210102318A (ko) 2018-12-06 2021-08-19 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이스-절단성 기질 및 세린 또는 시스테인 프로테이스-절단성 기질 그리고 이들의 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042576A1 (fr) * 1998-02-23 1999-08-26 Smithkline Beecham Plc Polypeptides du type cerebelline-2 et adn codant pour ces polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042576A1 (fr) * 1998-02-23 1999-08-26 Smithkline Beecham Plc Polypeptides du type cerebelline-2 et adn codant pour ces polypeptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERUBE NATHALIE G ET AL: "Cloning and characterization of CRF, a novel C1q-related factor, expressed in areas of the brain involved in motor function.", MOLECULAR BRAIN RESEARCH, vol. 63, no. 2, 8 January 1999 (1999-01-08), pages 233 - 240, XP002205214, ISSN: 0169-328X *
DATABASE EMBL [online] EBI, Hinxton, UK; 14 December 1999 (1999-12-14), "Homo sapiens BAC clone RP11-17N4 from 2, complete sequence.", XP002205216, Database accession no. AC016673 *
See also references of EP1328632A2 *
URADE Y ET AL: "PRECEREBELLIN IS A CEREBELLUM-SPECIFIC PROTEIN WITH SIMILARITY TO THE GLOBULAR DOMAIN OF COMPLEMENT C1Q B CHAIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 88, no. 3, 1991, 1991, pages 1069 - 1073, XP002205215, ISSN: 0027-8424 *
WADA C & OHTANI ET AL: "Molecular cloning of rat cerebellin-like protein cDNA which encodes a novel membrane-associated glycoprotein", MOLECULAR BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 9, no. 1/2, January 1991 (1991-01-01), pages 71 - 77, XP002103511, ISSN: 0169-328X *

Also Published As

Publication number Publication date
AU2001280464A1 (en) 2002-02-18
EP1328632A2 (fr) 2003-07-23
WO2002012475A2 (fr) 2002-02-14

Similar Documents

Publication Publication Date Title
WO2002014358A3 (fr) Nouvelles proteines secretees et leurs utilisations
WO2002008277A3 (fr) Acides nucleiques, vecteurs, cellules hotes, polypeptides et leurs utilisations
WO2001046420A3 (fr) Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
WO2002032939A3 (fr) Nouvelles proteines secretees et leurs utilisations
WO2002012475A3 (fr) Facteur associe a c1q, polypeptides homologues et utilisations therapeutiques associees
WO2001092493A3 (fr) Nouvelles aminopeptidases humaines 21956 et 25856, et utilisations
WO2002026801A3 (fr) Nouvelles proteines secretees et utilisations de ces dernieres
WO2002048361A3 (fr) Nouvelles proteines secretees et leurs utilisations
WO2002006330A3 (fr) Nouvelles molecules humaines de proteines kinases, 13237,18480,2245 ou 16228, et utilisations correspondantes
WO2002016578A3 (fr) Nouvelles proteines secretees et procedes d'utilisation de ces dernieres
WO2002000709A3 (fr) Polypeptides homologues de la cerebelline et utilisations therapeutiques de ces polypeptides
WO2002002771A3 (fr) Nouveau gene hsparc-11 et procedes de fabrication et d'utilisation de ce dernier
WO2002046408A3 (fr) Nouvelles proteines humaines, polynucleotides les codant et procedes d'utilisation
WO2003020912A3 (fr) Nouvelle proteine cark et molecules d'acides nucleiques et leurs utilisation
WO2001090365A3 (fr) Nouvelles molecules de proteine kinases 13305, et leurs utilisations
WO2002016579A3 (fr) Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers
WO2004013281A3 (fr) Nouvelles proteines et leurs utilisations
EP1529843A3 (fr) Protéines sécrétées et leurs utilisations
WO2002016588A3 (fr) A 15985, nouveau membre humain de la famille des proteines kinases serines/threonines, et ses utilisations
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2003035840A3 (fr) 69583 et 85924, nouveaux membres d'une famille de proteine kinase humaine et utilisations associees
WO2002018439A3 (fr) 52991, nouveau transporteur humain et utilisations associeesa
WO2003029778A3 (fr) Proteines secretees et utilisations associees
WO2004044126A3 (fr) Nouvelles proteines et leurs utilisations
WO2003083048A3 (fr) Nouvelles proteines secretees et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001958853

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001958853

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001958853

Country of ref document: EP